Abstract

The aim of our research was to reveal quantitative ratios existing between the pathways of cellular death in normal state, as well as in immunocomplex pathology. The proportion of different pathways of cell death (autophagy, apoptosis, necrosis) in autoimmune (systemic connective tissue diseases (SDCT) – rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic scleroderma (SSD) is a subject of age-related changes. On the one hand, aging process can be considered a genetically determined overall decrease in adaptive potential of the body, and a systemic age-related chronic inflammatory response, with a pronounced cytokine proinflammatory shift. On the other hand, a polygenic decrease in energy and information capacity of the cells, represent the basis of multisystem and multiorgan functional and metabolic disorders in SDCT. Blood plasma samples were analyzed in the patients of two age groups. The first group consisted of 10 SLE cases (4 men and 6 women, average age 43.8 years), 13 patients with RA (5 men and 8 women, average age 45.6 years), 7 SSD (women, average age 35.8 years), and 10 healthy donors (6 men and 4 women, average age 40.7 years). The second age group consisted of 9 SLE cases (2 men and 7 women, average age 69.8 years), 10 patients with RA (5 men and 5 women, average age 65.6 years), 5 patients with SSD (women, average age 65.7 years) and 12 healthy donors (normal biological aging – 7 men and 5 women, average age 64.7 years). The data presented in this paper were obtained with informed consent of the patients. When carrying out biomedical research, we followed internationally recognized ethical standards of the Helsinki Declaration (International Medical Association, 1996, revision 2013). The proportion of various cell death types (autophagy, apoptosis, necrosis) in autoimmune disorders (systemic diseases of connective tissue, SDCT), i.e., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and systemic scleroderma (SSD) proved to be subject to age-dependent changes. Close interaction were revealed between the ways of cellular death in SDCT (most pronounced in SLE), correlating with age changes and clinical manifestations of autoimmune process. In SDCT, the affected tissues exhibit all types of cellular death, however, degree of their expression depends on the disease nosology. Upon systemic diffuse pathology of connective tissue, autophagy (especially in case of SLE and RA) is directly involved in development of immune response and inflammatory process. In normal biological aging, like as in SDCT, one may observe a sharply increased activity of the metabolic trigger – AMP-activated protein kinase (AMPK), a sensor of intracellular energy, along with shifted acid-base equilibrium. The quantity of active oxygen radicals increases, oxidoreductive potential of the cells is changed, with activation of cellular destruction components. Activity of cytokine system in the organism is changed causing apoptosis regulation; expression of chaperons is decreased, and the immune-oxygenase homeostasis is also displaced. Inhibition of genetically determined process of death of cells (apoptosis) comprises the basis for development of autoimmune diseases. Transition of late apoptosis into secondary necrosis is accompanied by decrease of antioxidant protection and development of autoimmune pathology. The chaperon-mediated induction of immune response as the signaling mechanism of autophagy, being evolutionarily fixed in mammals only, may be the common central link and “the molecular switch” causing both development of autoimmune diseases of connective tissue, and aging processes.

Highlights

  • Вопрос о соотношении основных механизмов клеточной смерти при изучении аутоиммунной патологии, развивающейся при системных заболеваниях соединительной ткани в процессе старения организма, до настоящего времени остается актуальным и полностью не расшифрованным

  • reveal quantitative ratios existing between the pathways of cellular death

  • Kudryavtseva G.V., PhD, MD (Biology), Professor, Department of Diagnostics of Functional Systems, Faculty of Applied Mathematics/Management Processes, St. Petersburg State University, St. Petersburg, Russian Federation

Read more

Summary

Original articles

Шишкин В.И.1, Назаров П.Г.2, 3, Маленков Ю.А.1, Шишкин В.В.1, Кудрявцева Г.В.1, Картунен А.А.1. Цель работы – выявить количественные соотношения, существующие между путями клеточной смерти в норме и при диффузной иммунокомплексной патологии. Соотношение различных путей клеточной смерти (аутофагия, апоптоз, некроз) при аутоиммунных системных заболеваниях соединительной ткани (СЗСТ) – ревматоидном артрите (РА), системной красной волчанке (СКВ) и системной склеродермии (ССД) подвержено возрастным изменениям. С другой – в основе мультисистемности и полиорганности функционально-метаболических нарушений при системных заболеваниях соединительной ткани лежит полигенное снижение энергоинформационной емкости клеток. Картунен «О соотношении различных путей клеточной смерти на отдельных этапах онтогенеза в норме и при системных заболеваниях соединительной ткани» // Медицинская иммунология, 2020. Аутофагия в развитии системной диффузной патологии соединительной ткани (особенно в случае СКВ, а также РА) принимает непосредственное участие в формировании иммунного ответа и воспалительного процесса. Ключевые слова: аутофагия, апоптоз, некроз, системная красная волчанка, системная склеродермия, ревматоидный артрит

STATE AND SYSTEMIC DISEASES OF CONNECTIVE TISSUE
Материалы и методы
Findings
Результаты и обсуждение

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.